Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures of -$73K in Q2 FY2026

Q2 FY2026 capital expenditures was -$73K.

Context

  • Capital expenditures amounted to 171.3% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$73K-74.7% QoQ
Last fiscal yearDec 2025
-$2.31M+30.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+30.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(2.31M) USD
Year-over-year change
-30.5%

Capital Expenditures vs competitors

How ATTO compares with its peers on the latest reported figures

  • ATTO's FY2025 capital expenditures of $2.31M is the largest of the 10 companies compared; the peer median is $81K.
  • Its year-over-year change of +30.5% is the 4th highest of 9, against a peer median of -38.2%.
  • Capital expenditures amounts to 171.3% of revenue for ATTO, versus a peer median of 2.1%.
ATTO Competitors Peer median
Capital Expenditures for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATTOAttovia Therapeutics, Inc.FY2025$2.31M +30.5%—171.3%
CNTBConnect Biopharma Holdings LimitedFY2025$434K -42.1%-53.4%678.1%
ALMSAlumis Inc. Common StockLTM Jun 2026$401K -77.7%-35.3%5.4%
EVMNEvommune, Inc.LTM Mar 2026$318K ——3.2%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$219K +33.5%+371.0%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$81K -99.8%-43.2%1.0%
ZURAZura Bio LimitedLTM Mar 2026$77K -34.2%-78.9%—
ANABAnaptysBio, Inc.LTM Mar 2026$69K -81.1%-37.6%0.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$0 +100.0%+29.8%—
QTTBQ32 Bio Inc.LTM Mar 2026$0 +100.0%—0.0%
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ATTO) $81K-38.2%-37.6%2.1%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.